Association of Dual Specific Phosphatase 4 (DUSP4) Expression and Anthracycline-Based Neoadjuvant Chemotherapy Response in Breast Cancer

Authors

  • Prihantono Prihantono Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Mochammad Hatta Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Daniel Sampepajung Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Andi Asadul Islam Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Warsinggih Rahardjo Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • William Hamdani Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Christian Binekada Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Haryasena Haryasena Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Berti Nelwan Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Keywords:

Breast Cancer, Chemotherapy, Clinical Response, DUSP4, Intrinsic subtype, Anthracycline.

Abstract

Background: Chemotherapy is important component in the management of breast cancer.

References

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.

Rhodes A, Yip C. Comparison of breast cancer in Indonesia and Malaysia

Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer biology & medicine. 2014;11(2):101-15.

Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of Clinical Oncology. 2006;24(12):1940-9.

Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. European journal of pharmacology. 2013;717(1):58-66.

Lee A, Lim W, Moon B-I, Paik N-S, Koh S-H, Song J-Y. Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline-and taxane-based chemotherapy. Journal of breast cancer. 2011;14(4):283-8.

Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, et al. Alteration of topoisomerase II

Liu Y, Du F, Chen W, Yao M, Lv K, Fu P. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Experimental cell research. 2013;319(20):3140-9.

Luqmani Y. Mechanisms of drug resistance in cancer chemotherapy. Medical Principles and Practice. 2005;14(Suppl. 1):35-48.

Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC cancer. 2013;13(1):1.

Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, et al. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PloS one. 2010;5(12):e15630.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature medicine. 2012;18(7):1052-9.

Smith A, Price C, Cullen M, Muda M, King A, Ozanne B, et al. Chromosomal localization of three human dual specificity phosphatase genes (DUSP4, DUSP6, and DUSP7). Genomics. 1997;42(3):524-7.

Huang C-Y, Tan T-H. DUSPs, to MAP kinases and beyond. Cell & bioscience. 2012;2(1):1.

CAMPS M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. The FASEB Journal. 2000;14(1):6-16.

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer research. 2013;73(20):6346-58.

Rottenberg S, Jonkers J. MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. Breast Cancer Research. 2012;14(6):1-2.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009;45(2):228-47.

Kim H, Jang SM, Ahn H, Sim J, Yi K, Chung Y, et al. Clinicopathological Significance of Dual-Specificity Protein Phosphatase 4 Expression in Invasive Ductal Carcinoma of the Breast. Journal of breast cancer. 2015;18(1):1-7.

Sim J, Yi K, Kim H, Ahn H, Chung Y, Rehman A, et al. Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma. Gastroenterology research and practice. 2015;2015.

Adams J, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-37.

Armes JE, Hammet F, de Silva M, Ciciulla J, Ramus SJ, Soo W-K, et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene. 2004;23(33):5697-702.

Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, et al. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Breast cancer research and treatment. 2014;148(1):211-20.

Downloads

Published

2017-02-15

How to Cite

Prihantono, P., Hatta, M., Sampepajung, D., Islam, A. A., Rahardjo, W., Hamdani, W., Binekada, C., Haryasena, H., & Nelwan, B. (2017). Association of Dual Specific Phosphatase 4 (DUSP4) Expression and Anthracycline-Based Neoadjuvant Chemotherapy Response in Breast Cancer. International Journal of Sciences: Basic and Applied Research (IJSBAR), 31(3), 125–133. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/6906

Issue

Vol. 31 No. 3 (2017)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.